Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
Sign Up to like & getrecommendations! Published in 2017 at "Nature Communications"
DOI: 10.1038/ncomms13671
Abstract: Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease. To understand this aggression, here we profile the genomes… read more here.
Keywords: brca2 mutations; germline brca2; mutant pca; brca2 ... See more keywords
Incidence of germline BRCA1 and BRCA2 mutations among Filipinos.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13628
Abstract: e13628Background: The Philippines has the highest reported incidence of breast cancer (BC) in Southeast Asia, with a rate of 47.7 per 100,000 per year. 5 to 10% of BC results from a hereditary pred... read more here.
Keywords: incidence; brca2 mutations; incidence germline; brca1 brca2 ... See more keywords
Investigating men’s motivations to engage in genetic screening for BRCA1 and BRCA2 mutations
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0265387
Abstract: BRCA1 and BRCA2 mutations are associated with an increased risk of developing numerous cancers, including breast, ovarian, pancreatic, melanoma and prostate cancer. Men face BRCA-related cancer risks as women do. However, there is considerably less… read more here.
Keywords: brca1; brca2 mutations; brca1 brca2; screening brca1 ... See more keywords
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051180
Abstract: Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Although approximately 65% of patients are diagnosed in stage I, more than 50% have relapsed disease, and effective therapies for recurrent and advanced… read more here.
Keywords: brca2 mutations; review; uterine leiomyosarcoma; status current ... See more keywords